Response Biomedical Corp. (fka RPBIF)

[OttomanRosendahl]

Global Biotech Investing - Response Biomedical sample depot admission 12:06 06.10.09 Endingen (aktiencheck.de AG) - which experts of " Global Biotech Investing" takes up the Response Biomedical share (profile) to the sample depot.

In the course of a heavy financing round the society did Canadian dollar (CAD) to 12 millions in March 2006 a radical step and replaced executive committee and supervisory board. Thus it wants to set the focus after years of the development now completely purposefully on the commercialization. Proven experts, who had been and others already successfully in the sale at that time of the vaccine manufacturer ID Biomedical involved in GlaxoSmithKline, would form now the core of the new management. According to opinion of the analysts of MIDAS Research such a scenario is conceivable quite also with Response Biomedical.


The Canadian diagnostics developer has up-to-date eleven immunoassay based rapid tests for marketing certified. The clinical tests were marketed over the marketing partners 3M Healthcare, Roche Dx and Shionogie. Additionally sell Response Biomedical in self-direction test for agents at government organizations and can from orders hardly save itself at present. Co-operation with the strong marketing partners shows in the meantime first positive effects: Roche Dx began in April 2009 with the marketing of the Kardio rapid tests in the USA, whereby the conversions " Clinical Products" already in the 2nd quarter around 370% are upward shot. The analysts of MIDAS Research would already prognosticate a substantial gross income increase of CAD 5 millions on CAD 11 million for this reason for 2009. During a further expected turnover doubling on CAD Response Biomedical will presumably reach 24 millions 2010 the profit area. In the coming weeks expect one move new flow. The analysts of MIDAS Research would therefore expect a strong upward motion already shortly. On view of twelve to 24 months they would think capable of to the share certificate even a smooth doubling, whereby the paper would be still clearly too cheap in the comparison to the Peergroup (e.g. Quidel) even then.

In view of this striking underestimation and the chance for short term profits on exchange the experts of " pack themselves; Global Biotech Investing" immediately a tidy position of the Response Biomedical share into their sample depot.


http://www.ariva.de/news/Response-Biomedical-Musterdepotaufnahme-Global-Biotech-Investing-3092419